Insulin glargine is a long-acting insulin analog used to treat diabetes. It works by maintaining blood glucose levels throughout the day and night. Insulin Glargine helps in mimicking the body's natural basal insulin levels and stabilizes blood sugar by keeping it within normal ranges. It is safer than other human insulin counterparts as it does not peak like regular human insulin and has a steady release pattern. Insulin Glargine is used as part of a diabetes treatment plan that may include diet, exercise, and other diabetes medications.
The Global Insulin Glargine Market is estimated to be valued at US$ 1.68 Bn in 2024 and is expected to exhibit a CAGR of 19% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the Insulin Glargine market are Siemens Healthineers, Mckesson Corporation, IBM Corporation, Genpact Limited, Epic Systems Corporation, Deloitte, Cerner Corporation, Accenture Plc, Allscripts Healthcare Solutions Inc., and Cognizant Technology Solutions Corporation, among others. The growing prevalence of diabetes across regions is fueling the demand for insulin glargine globally. As per the International Diabetes Federation (IDF), around 537 million adults were living with diabetes in 2021 worldwide and this number is expected to rise to 783 million by 2045. Technological advancements like integration ofconnected healthcare platforms, AI-driven monitoring devices are enabling efficient tracking and control of blood glucose levels thereby propelling the insulin glargine market growth.
Market Trends
The key trends in the Insulin Glargine Market Demand include growing adoption of combo insulin technologies and increasing popularity of wearable insulin delivery devices. Combo insulin like insulin glargine and liraglutide combination offers dual action of basal insulin and GLP-1 agonist with enhanced glycemic control. Wearable insulin delivery devices like insulin patches are gaining traction as they provide non-invasive and discreet insulin administration with increased compliance.
Market Opportunities
The rising geriatric population suffering from diabetes and growing healthcare expenditure in emerging nations presents significant growth opportunities in the insulin glargine market. Furthermore, the development of long-acting premium insulin analogs with more stable release profiles and reduced adverse effects will further aid the market expansion over the forecast period.
Get more insights on Insulin Glargine Market
About Author:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian